Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer

Maurie Markman, MD

August 22, 2022

Currently, eight genes (EGFR, ALK, ROS1, BRAF, NTRK, MET, KRAS, and RET) have therapies that have been approved by the US Food and Drug Administration (FDA). Several other genes are being targeted by drugs that are undergoing clinical trials. About 35% of patients with advanced nonsquamous NSCLC have a driver mutation targetable by an FDA-approved agent.

Learn more about targeted therapies for NSCLC.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Maurie Markman. Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer - Medscape - Aug 22, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Maurie Markman, MD

Comments

Email This

Feedback